CRISPR Therapeutics General Counsel James R. Kasinger disposes of 1,990 common shares worth $119,481.19

Bitget2026/10/08 21:35

James R. Kasinger, general counsel and secretary, exercised stock options for 1,990 common shares at $13.62 on Oct. 6, 2026. He sold 1,990 common shares at a weighted average price of $60.0408 on the same day. Directly held common shares fell to 94,784 from 96,774. Directly held stock options declined to 81,242 following the exercise. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-418101), on October 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Canadian used car dealer UC Automotive (UCAU.RC.US) files for IPO in the US: aims to raise 29 million USD and list on Nasdaq

Canadian used car dealer UC Automotive has applied for a Nasdaq IPO, aiming to raise up to $29 million, with its main focus on the Greater Vancouver market. Kingswood is the sole underwriter.

智通财经•2026/11/09 06:12

UniCredit: Third-quarter net profit reaches 3.26 billion euros, exceeding expectations

格隆汇•2026/11/09 06:11

UK funds significantly reduced their holdings in SpaceX last week and had fully exited Tesla as of April.

格隆汇•2026/11/09 05:55

Swiss Franc weakens as Fed hawkish outlook lifts USD/CHF

FXStreet•2026/11/09 05:45